Work

Iguratimod plus low-dose rituximab as second-line treatment in adults with primary immune thrombocytopenia: A multicenter, open-label, randomized, controlled, Phase 2 trial

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-3044

Authors: Qiu-Sha Huang, Zhuo-Yu An, Peng Zhao, Qi Chen, Jin Wu, Hai-Xia Fu, Yujun Dong, Hongmei Jing, Liping Dou, Hui Liu, Yi Liu, Lanping Xu, Xiaojun Huang, Xiaohui Zhang

Institutions: Peking University, Peking University People's Hospital, Peking University First Hospital, Peking University Third Hospital, Chinese PLA General Hospital, Beijing Hospital

Language: English

Topic: Platelet Disorders and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7108711796

Cites:

Cited by:

Related to: